Atom Investors LP Buys 120,822 Shares of Dianthus Therapeutics, Inc. $DNTH

Atom Investors LP raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 197.9% in the fourth quarter, Holdings Channel reports. The fund owned 181,860 shares of the company’s stock after purchasing an additional 120,822 shares during the quarter. Atom Investors LP’s holdings in Dianthus Therapeutics were worth $7,494,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the second quarter worth about $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $40,000. Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the third quarter worth about $64,000. Tower Research Capital LLC TRC lifted its holdings in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of research reports. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Robert W. Baird raised their price objective on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Finally, Oppenheimer raised their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $78.88 on Wednesday. The firm has a market cap of $4.31 billion, a PE ratio of -19.10 and a beta of 1.18. The firm’s fifty day moving average is $86.88 and its 200-day moving average is $65.73. Dianthus Therapeutics, Inc. has a 52 week low of $16.64 and a 52 week high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Buying and Selling

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. This represents a 86.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Ryan Savitz sold 8,224 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $89.84, for a total transaction of $738,844.16. Following the sale, the executive vice president directly owned 8,224 shares of the company’s stock, valued at $738,844.16. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 149,121 shares of company stock valued at $12,635,454 in the last three months. Insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.